Common Stock, par value $0.0001 per share
- Symbol
- FLGT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Fulgent Genetics, Inc.
FLGTNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On May 21, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, presenting interim data from the Company's open-label, randomized Phase 2 study, was released.…
Company context
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Current securities
Registered securities in this filing
FULGENT GENETICS, INC. · 8-K · Filed 2026-05-21
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On May 21, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, presenting interim data from the Company's open-label, randomized Phase 2 study, was released. A copy of the Company’s press release containing this information is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Filed exhibits (1)
EX-99.1 2 flgt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting EL MONTE, Calif. - May 21, 2026 - Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago. The abstract is entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”. It presents interim data from the Company’s open-label, randomized Phase 2 study (NCT06332092). The study was designed to evaluate the efficacy of two different dosing regimens and to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab …
Open exhibit ↗